Want to see ACH full AI Analyst Report?
ACH Stock Chart & Stats
$2.80
-$0.12(-4.11%)
At close: 4:00 PM EDT
$2.80
-$0.12(-4.11%)
Day’s Range― - ―
52-Week Range$1.84 - $7.10
Previous Close$2.79
Volume1.15M
Average Volume (3M)1.12M
Market Cap
$236.64M
Enterprise Value$2.01K
Total Cash (Recent Filing)$336.88M
Total Debt (Recent Filing)$2.17B
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Aug 10, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-14.05
Shares Outstanding76,583,700
10 Day Avg. Volume949,424
30 Day Avg. Volume1,122,390
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.47
Price to Sales (P/S)0.08
P/FCF Ratio-0.71
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$5.00Price Target Upside78.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.41
Revenue Forecast (FY)$2.58B
Bulls Say, Bears Say
Bulls Say
Margin TransformationA shift to ~50% gross margins and double‑digit EBITDA as a pure‑play home‑based care operator materially improves long‑run profitability potential. Higher gross margins create durable cushion vs. product cost swings, enable reinvestment in growth and adherence programs, and help absorb interest and SG&A over time if sustained.
Debt Maturity Extension And RestructuringCompleted exchanges and new secured notes extend maturities and double weighted‑average debt life, materially reducing near‑term refinancing risk. The new revolver and restructured covenants give time to execute cost savings and de‑leverage up to ~$115M, improving structural stability despite higher coupons.
Liquidity And Covenant ComplianceStrong reported liquidity and covenant compliance provide an operational runway to implement margin and collection improvements. Ample cash and revolver capacity reduce default risk, support seasonal working capital needs, and lower the chance of forced asset sales while refinancing completes.
Bears Say
Sharp Revenue ContractionA ~42% TTM revenue decline and deep net losses indicate a structurally smaller revenue base and lost scale. Reduced volume weakens purchasing leverage and operating leverage, making margin recovery harder and increasing sensitivity to category underperformance and collections issues over the medium term.
High Leverage & Negative EquityElevated debt with negative equity weakens the capital structure and limits strategic flexibility. Even with maturity extension, negative equity heightens creditor influence, raises refinancing and covenant risk, and increases the cost of capital, constraining investments and making downside scenarios more severe.
Weak Cash GenerationA persistent swing to negative operating and free cash flow undermines the company’s ability to service debt and fund growth internally. Reliance on one‑time asset sales and external financing increases execution risk and could force deeper cost cuts if collections and margins do not sustainably improve.
Accendra Health News
ACH FAQ
What was Accendra Health’s price range in the past 12 months?
Accendra Health lowest stock price was $1.84 and its highest was $7.10 in the past 12 months.
What is Accendra Health’s market cap?
Accendra Health’s market cap is $236.64M.
When is Accendra Health’s upcoming earnings report date?
Accendra Health’s upcoming earnings report date is Aug 10, 2026 which is tomorrow.
How were Accendra Health’s earnings last quarter?
Accendra Health released its earnings results on May 11, 2026. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.098 by $0.058.
Is Accendra Health overvalued?
According to Wall Street analysts Accendra Health’s price is currently Undervalued.
Does Accendra Health pay dividends?
Accendra Health pays a Quarterly dividend of $0.002 which represents an annual dividend yield of N/A. See more information on Accendra Health dividends here
What is Accendra Health’s EPS estimate?
Accendra Health’s EPS estimate is -0.08.
How many shares outstanding does Accendra Health have?
Accendra Health has 76,583,700 shares outstanding.
What happened to Accendra Health’s price movement after its last earnings report?
Accendra Health reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.098. Following the earnings report the stock price went up 8.659%.
Which hedge fund is a major shareholder of Accendra Health?
Currently, no hedge funds are holding shares in ACH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Accendra Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (78.57% Upside)
$5.00 (78.57% Upside)
Blogger Sentiment
Bullish
ACH Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 635.6K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.19%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-50.25%
Trailing 12-Months
Company Description
Accendra Health
Accendra Health, Inc., along with its subsidiaries, operates globally as a comprehensive provider of healthcare solutions. The organization is structured into two primary operational divisions: Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment offers a wide array of goods and support services to both healthcare providers and manufacturers. Its extensive catalog includes medical and surgical supplies, featuring both established brands and its own proprietary merchandise. This segment also delivers crucial services to healthcare providers, such as supplier relationship management, advanced analytics, inventory optimization, and clinical supply oversight. Furthermore, it provides outsourced logistics and marketing assistance programs to its vendor partners. The Patient Direct segment is dedicated to delivering products and services for at-home patient care. Its offerings encompass critical therapeutic fields such as diabetes management, home-based respiratory support, and obstructive sleep apnea therapy. This division also supplies various other types of home medical equipment, as well as specialized patient care products for conditions like ostomy, wound management, urological needs, and incontinence. Accendra Health serves a diverse client base directly, including large multi-facility healthcare systems, independent hospitals, surgical facilities, and physicians' practices. Additionally, it reaches customers indirectly through third-party distribution channels. The enterprise was formerly known as Owens & Minor, Inc., adopting the name Accendra Health, Inc. in December 2025. Founded in 1882, its headquarters are located in Glen Allen, Virginia.
ACH Company Deck
ACH Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a mix of strong strategic and financial progress — notably the successful separation, margin transformation, balance sheet optimization commitments, $82M equipment sale and $52M one‑time gain, and operational wins in sleep therapy — while also acknowledging meaningful near‑term pressures: a 6.8% revenue decline, collection and cost headwinds, slightly negative free cash flow in Q1, and an expected ~ $40M annualized increase in cash interest post‑refinancing. Management emphasized that underlying revenue (ex‑large payor) was roughly +1% and that debt reduction and cost‑savings remain priorities, framing the near‑term drawbacks as manageable steps in service of a stronger long‑term standalone profile.View all ACH earnings summariesACH Stock 12 Month Forecast
Average Price Target
$5.00
▲(78.57% Upside)
Ownership Overview
20.56% Insiders
19.36% Mutual Funds
0.13% Other Institutional Investors
46.50% Public Companies and
Individual Investors